Drug Profile
Research programme: antiviral agents - REPLICor
Alternative Names: REP 9Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator REPLICor
- Class Oligonucleotides
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections; Viral infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Viral-infections in Canada
- 10 Apr 2006 Preclinical data from a media release have been added to the Viral infections antimicrobial activity section